| Title |
Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer
|
|---|---|
| Published in |
OncoTargets and therapy, July 2015
|
| DOI | 10.2147/ott.s86637 |
| Pubmed ID | |
| Authors |
Manish Kohli, Charles YF Young, Donald J Tindall, Debashis Nandy, Kyle M McKenzie, Graham H Bevan, Krishna Vanaja Donkena |
| Abstract |
This study tested the potential of circulating RNA-based signals as predictive biomarkers for docetaxel response in patients with metastatic castration-resistant prostate cancer (CRPC). RNA was analyzed in blood from six CRPC patients by whole-transcriptome sequencing (total RNA-sequencing) before and after docetaxel treatment using the Illumina's HiSeq platform. Targeted RNA capture and sequencing was performed in an independent cohort of ten patients with CRPC matching the discovery cohort to confirm differential expression of the genes. Response to docetaxel was defined on the basis of prostate-specific antigen levels and imaging criteria. Two-way analysis of variance was used to compare differential gene expression in patients classified as responders versus nonresponders before and after docetaxel treatment. Thirty-four genes with two-fold differentially expressed transcripts in responders versus nonresponders were selected from total RNA-sequencing for further validation. Targeted RNA capture and sequencing showed that 13/34 genes were differentially expressed in responders. Alpha defensin genes DEFA1, DEFA1B, and DEFA3 exhibited significantly higher expression in responder patients compared with nonresponder patients before administration of chemotherapy (fold change >2.5). In addition, post-docetaxel treatment significantly increased transcript levels of these defensin genes in responders (fold change >2.8). Our results reveal that patients with higher defensin RNA transcripts in blood respond well to docetaxel therapy. We suggest that monitoring DEFA1, DEFA1B, and DEFA3 RNA transcripts in blood prior to treatment will be helpful to determine which patients are better candidates to receive docetaxel chemotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 28% |
| Student > Master | 4 | 16% |
| Student > Bachelor | 3 | 12% |
| Student > Ph. D. Student | 2 | 8% |
| Student > Doctoral Student | 2 | 8% |
| Other | 1 | 4% |
| Unknown | 6 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 32% |
| Agricultural and Biological Sciences | 5 | 20% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Nursing and Health Professions | 1 | 4% |
| Arts and Humanities | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 6 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2022.
All research outputs
#7,047,316
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#356
of 3,016 outputs
Outputs of similar age
#75,553
of 277,610 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 81 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,610 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.